All In Biotech

Drug Trial Radar · NCT00147758

WelChol® and Sulfonylurea in Treating Patients With Type 2 Diabetes

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of WelChol® in Type 2 Diabetics With Inadequate Glycemic Control on Sulfonylurea Monotherapy or Sulfonylurea Therapy in Combination With Other Oral Anti-Diabetic Agents

Last checked: Nov 19, 2026Latest source record: Jan 18, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

400

Actual

Start

Jun 2004

Primary completion

Aug 2006

Study completion Aug 2006

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
First posted
Sep 7, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to see how safe and effective and tolerable the use of colesevelam hydrochloride is for type 2 diabetes when added to sulfonylurea alone or in combination with other anti-diabetic drugs.

Conditions

  • Type 2 Diabetes

Interventions

  • Colesevelam hydrochlorideDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the additional lowering of HbA1c achieved by addition of colesevelam hydrochloride to current antidiabetic therapy

Locations

47 sites in 3 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Tuscumbia, Alabama

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Searcy, Arkansas

  • Site not named

    Concord, California

  • Site not named

    Irvine, California

  • Site not named

    La Jolla, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Gatos, California

  • Site not named

    West Hills, California

  • Site not named

    Coral Gables, Florida

  • Site not named

    Miami, Florida

  • Site not named

    New Port Richey, Florida

  • Site not named

    Pembroke Pines, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Boston, Massachusetts

  • Site not named

    Kansas City, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Rochester, New York

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Hickory, North Carolina

  • Site not named

    Statesville, North Carolina

  • Site not named

    Winston-Salem, North Carolina

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Cleveland, Ohio

  • Site not named

    Marion, Ohio

  • Site not named

    Perrysburg, Ohio

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Tulsa, Oklahoma

  • Site not named

    Portland, Oregon

  • Site not named

    Beaver, Pennsylvania

  • Site not named

    Charleston, South Carolina

  • Site not named

    Bristol, Tennessee

  • Site not named

    Dallas, Texas

  • Site not named

    Houston, Texas

  • Site not named

    Midland, Texas

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.